Compare Cipla with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs GLENMARK PHARMA - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA GLENMARK PHARMA CIPLA/
GLENMARK PHARMA
 
P/E (TTM) x 23.7 12.1 195.1% View Chart
P/BV x 2.4 1.7 139.4% View Chart
Dividend Yield % 0.7 0.6 119.1%  

Financials

 CIPLA   GLENMARK PHARMA
EQUITY SHARE DATA
    CIPLA
Mar-19
GLENMARK PHARMA
Mar-19
CIPLA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs678712 95.3%   
Low Rs484484 100.0%   
Sales per share (Unadj.) Rs198.2349.6 56.7%  
Earnings per share (Unadj.) Rs18.532.8 56.5%  
Cash flow per share (Unadj.) Rs35.044.3 78.9%  
Dividends per share (Unadj.) Rs3.002.00 150.0%  
Dividend yield (eoy) %0.50.3 154.3%  
Book value per share (Unadj.) Rs186.3198.6 93.8%  
Shares outstanding (eoy) m805.70282.17 285.5%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.91.7 171.5%   
Avg P/E ratio x31.418.2 172.0%  
P/CF ratio (eoy) x16.613.5 123.2%  
Price / Book Value ratio x3.13.0 103.6%  
Dividend payout %16.26.1 265.5%   
Avg Mkt Cap Rs m468,031168,625 277.6%   
No. of employees `00022.612.0 188.1%   
Total wages/salary Rs m28,56520,561 138.9%   
Avg. sales/employee Rs Th7,053.18,196.0 86.1%   
Avg. wages/employee Rs Th1,261.51,708.1 73.9%   
Avg. net profit/employee Rs Th659.1768.5 85.8%   
INCOME DATA
Net Sales Rs m159,71098,655 161.9%  
Other income Rs m4,7662,081 229.0%   
Total revenues Rs m164,475100,736 163.3%   
Gross profit Rs m30,97315,858 195.3%  
Depreciation Rs m13,2633,259 407.0%   
Interest Rs m1,6843,346 50.3%   
Profit before tax Rs m20,79111,335 183.4%   
Minority Interest Rs m-1720-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m01,672 0.0%   
Tax Rs m5,6953,756 151.6%   
Profit after tax Rs m14,9249,250 161.3%  
Gross profit margin %19.416.1 120.6%  
Effective tax rate %27.433.1 82.7%   
Net profit margin %9.39.4 99.7%  
BALANCE SHEET DATA
Current assets Rs m124,26666,968 185.6%   
Current liabilities Rs m37,71540,211 93.8%   
Net working cap to sales %54.227.1 199.8%  
Current ratio x3.31.7 197.8%  
Inventory Days Days9183 108.7%  
Debtors Days Days9581 116.8%  
Net fixed assets Rs m105,19033,322 315.7%   
Share capital Rs m1,611282 571.0%   
"Free" reserves Rs m148,51155,770 266.3%   
Net worth Rs m150,12356,052 267.8%   
Long term debt Rs m38,30135,738 107.2%   
Total assets Rs m239,633132,888 180.3%  
Interest coverage x13.34.4 304.1%   
Debt to equity ratio x0.30.6 40.0%  
Sales to assets ratio x0.70.7 89.8%   
Return on assets %6.99.5 73.1%  
Return on equity %9.916.5 60.2%  
Return on capital %11.817.8 66.4%  
Exports to sales %34.70-   
Imports to sales %00-   
Exports (fob) Rs m55,419NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m57,41062,998 91.1%   
Fx outflow Rs m19,04122,859 83.3%   
Net fx Rs m38,36840,140 95.6%   
CASH FLOW
From Operations Rs m16,91113,242 127.7%  
From Investments Rs m-16,687-6,990 238.7%  
From Financial Activity Rs m-3,487-7,387 47.2%  
Net Cashflow Rs m-3,451-2,971 116.2%  

Share Holding

Indian Promoters % 16.0 48.3 33.1%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 6.9 176.8%  
FIIs % 23.7 34.4 68.9%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 10.5 249.5%  
Shareholders   161,166 56,727 284.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   PFIZER  GSK PHARMA  PANACEA BIOTECH  DR. REDDYS LAB  ABBOTT INDIA  

Compare CIPLA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps 470 Points; Energy and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended deep in the red. The BSE Sensex fell over 550 points intraday and breached the 36,000 mark.

Related Views on News

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Sep 19, 2019 (Close)

TRACK CIPLA

CIPLA - LUPIN COMPARISON

COMPARE CIPLA WITH

MARKET STATS